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Genetic associationRenal failure has a complex phenotype resulting from an underlying kidney disease as well as environmental
and genetic factors. In the present study we performed a systematic review and meta-analyses to evaluate the
association of the A1166C polymorphism of Angiotensin II type 1 Receptor gene (AGTR1) with Chronic Kidney
Disease (CKD), End Stage Renal Disease (ESRD), IgA Nephropathy (IgAN) and Vesicoureteral Reﬂux (VUR)
as well as the association of A1332G polymorphism of Angiotensin II type 2 Receptor (AGTR2) gene with
Vesicoureteral Reﬂux (VUR). We found that neither AGTR1 Α1166C, nor AGTR2 A1332G polymorphisms were
signiﬁcantly associated with any of the aforementioned renal diseases, suggesting that they cannot be used as
predictive markers in either general or subgroup ethnic populations.
© 2014 Braliou et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Chronic Kidney Disease (CKD) is a global public health problem
reaching high prevalence and demanding elevated health costs. It is
characterized by a slow, progressive and irreversible decline of renal
function; it is usually asymptomatic and thus untreated [1]. National
Kidney Foundation guidelines classify the severity of Chronic Kidney
Disease in ﬁve stages. Stage 5 CKD is often called End Stage Renal Dis-
ease (ESRD) and is characterized by severe illness with poor life expec-
tancy if untreated. However, ESRD is a complex disorder with a variety
of phenotypes emanating from a variety of underlying kidney disorders
in conjunction with genetic and environmental factors as well as other
preexisting or secondary clinical entities [2]. Treatment in ESRD is
renal replacement which encounters dialysis or kidney transplantation
[3]. Persons at high risk predominantly suffer from diabetes mellitus or
hypertension [4]. Nevertheless, many common adult-onset kidney disor-
ders may be due to various risk-alleles and to interactions between vari-
ous genes and gene–environment interactions [5].
Immunoglobulin A Nephropathy (IgAN), where IgA deposits are
found in the glomerular mesangial area, is the most common form of
glomerulonephritis world-wide and leads to ESRD in about 20% of thence and Biomedical Informatics,
, Greece. Tel.: +30 2231066914;
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s/by/4.0/).cases [6,7]. Vesicoureteral Reﬂux (VUR) is a formof Congenital Anomaly
of the Kidney and Urinary Tract (CACUT) [8]. It is a very common
urological cause of renal insufﬁciency in children, culminating to
ESRD in children, adolescents, and young adults, which is potentially
preventable [9].
The Renin–Angiotensin System (RAS) inﬂuences sodium balance,
extracellular ﬂuid (ECF) volume, and renal and systemic vascular resis-
tance. Thus, the RAS serves as one of the most powerful regulators of
arterial blood pressure [10]. The primary effector molecule of this
system is angiotensin II (ANG II) and is formed after two cleavage
steps by Renin and Angiotensin Converting Enzyme (ACE). The ANG II
mediates its actions via twoGprotein-coupled receptors, the Angiotensin
II type 1 Receptor (AGTR1) and Angiotensin II type 2 Receptor (AGTR2)
[10,11].
ANG II binds to AGTR1 and induces systemic vasoconstriction, a
situation that leads to elevated peripheral resistance, and ultimately
increases blood pressure. Arterial hypertension (HT) is frequently asso-
ciated with chronic renal failure, and it is themost important risk factor
for the progression of renal failure. In summary, RAS proteins convey
the response of the kidneys to effective circulating volume thus regulat-
ing salt and water handling by the kidney. This ﬁne-tuned molecular
balancemay be adversely inﬂuenced by a geneticallymediated variabil-
ity of RAS protein variants, leading to early damage of the cardiovascular
or renal organ systems [10].
Although yet quite complex, there is strong evidence of genetic
susceptibility in renal failure [5,10,12]. In the present study,we attempted
to clarify the genetic association of polymorphisms of the angiotensin
receptors with renal diseases and discus the possibility that these poly-
morphisms may be used as prognostic markers for renal failure.k of Computational and Structural Biotechnology. This is an open access article under
Table 1
Polymorphisms of AGTR1 and AGTR2 genes studied for their association with renal
diseases.
Disease Gene SNP Patients/controls Number of
studies
ESRD AGTR1 A1166C/rs5186 2596/3866 17
ESRD AGTR1 C521T 1
ESRD AGTR1 A1138T 1
ESRD AGTR1 AG214CC 1
CKD AGTR1 A1166C/rs5186 812/4252 8
CKD AGTR1 C573T 1
CKD AGTR1 C521T 2
CKD AGTR1 A1138T 1
CKD AGTR1 AG214CC 1
CKD AGTR1 G163A 2
CKD AGTR2 A1332G/rs5194 1
IgAN AGTR1 A1166C/rs5186 785/1373 5
VUR AGTR1 A1166C/rs5186 174/216 3
VUR AGTR2 A1332G/rs5194 352/790 3
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2.1. Literature search
A comprehensive literature search until November 2012 was per-
formed and 30 independent studies were retrieved that could fulﬁll all
the eligible criteria. The keywords that were used for the search were:
AGTR, AGTR1, AGTR1B, AGTR2, ‘ANGIOTENSIN RECEPTOR’, ‘ANGIOTEN-
SIN II RECEPTOR’, GENE, VARIANT, POLYMORPHISM, MUTANT,
MUTATION, ALLELE, ‘CHRONIC KIDNEY DISEASE’, ‘KIDNEY FAILURE’
‘END-STAGE KIDNEY DISEASE’, ‘END-STAGE RENAL DISEASE’, ‘END-
STAGE RENAL FAILURE’, DIALYSIS, ‘IgA GLOMERULONEPHRITIS’, ‘IgA
NEPHROPATHY’, ‘VESICOURETERAL REFLUX’, VUR and combinations of
them. To enrich the investigation, references of published studies were
incorporated.
2.2. Data extraction
Data extraction from each study was performed by two reviewers
according to the eligibility criteria. All problems of poor agreement,
when they occurred, were resolved after discussion with a third inves-
tigator and the necessary data were stratiﬁed in spreadsheet. The fol-
lowing data were extracted from each study: Pubmed ID, ﬁrst author's
name, year of publication, geographical location and ethnicity of popu-
lation studied, and total number of the subjects (cases and control
groups). The distributions of alleles and genotypes were calculated in
cases and controls for each study and are shown in Tables S1–S5.
When a case–control study was designed according to a family based
model, the family-trio model was encountered that distinguishes be-
tween affected offspring and non-affected parents (controls) and analy-
sis was performed according to the transmission disequilibrium test
(TDT) [13].
2.3. Statistical analysis
Odds ratio (OR) was used as the effect size of choice to test the
association between the mutant alleles or genotypes (as deﬁned in
each polymorphism case), and the disease phenotypes. In case of a
zero cell, a continuity correction was applied by adding 0.5 to all cells
of the contingency table. Data were combined using a random-effects
method [14] with inverse-variance weights, and ORs were calculated
along with their 95% CIs for each genotype or allele contrast. The
between study heterogeneity was evaluated using the chi-square
based Cochran's Q statistic and the consistency index (I2) [15].
The multivariate random-effects method of meta-analysis was also
applied as a more advanced method for testing gene–disease associa-
tions. In this framework, the two summary log-odds ratios related to
the risk allele, e.g. the log-odds ratio of heterozygotes vs. homozygotes
(AB vs. AA) and the log-odds ratio of homozygotes for the risk allele
vs. homozygotes for thewild type allele (BB vs. AA), aremodeled simul-
taneously as a bivariate response. This method has several important
properties, since it can infer and quantify the genetic model of inheri-
tance directly, by estimating the ratio λ of the two log-odds ratios
[16–19]. This way, we avoid multiple testing and thus the inﬂation of
the Type I error rate. Stata 10 (StataCorp) was the statistical package
that was used for all the analyses. Results with p-value b0.05 were
considered statistically signiﬁcant.
To estimate possible publication bias, the rank correlationmethod of
Begg and Mazumdar [20] was used. Additionally, the ﬁxed effects
regression method of Egger was also recruited [21]. Inﬂuential meta-
analysis was further performed, by removing an individual study each
time, and re-calculating the effects estimates (ORs) and heterogeneity.
In order to identify a possible trend of the combined estimate over
years, a condition that often introduces a special kind of bias (“Proteus
phenomenon”), cumulative meta-analysis was also performed. Time-
trend was detected using two methods: the standard cumulativemeta-analysis [22–24] approach, where we visually inspect the plot,
and a more recently proposed regression-based method [25].
3. Results
A literature search was performed to identify all studies assessing
the association of Angiotensin II type 1 Receptor (AGTR1) and Angiotensin
II type 2 Receptor (AGTR2) gene polymorphisms with renal diseases.
Meta-analyses were performed for the polymorphisms for which at
least three studies were found. Polymorphisms of both genes related
to disease phenotypes along with the number of studies identiﬁed and
numbers of patients and controls included in each meta-analysis are
shown in Table 1.
3.1. A1166C polymorphism of AGTR1 gene
In a meta-analysis to test the putative association of the A1166C
(rs5186) polymorphism of the AGTR1 gene with ESRD 109 studies
were retrieved. Nevertheless, only 17 studies were included [26–42]
that fulﬁlled the selection criteria and comprised of 2596 patients and
3866 controls. One study [32] had a family based design, (trio), and it
was analyzedwith the transmission disequilibrium test (TDT) according
to the method presented in [13].
The characteristics of each study are shown in Table 2A,while details
about alleles and genotypes are shown in Table S1. No statistical signif-
icant associationwas found for the per-allele contrast since ORwas 1.10
with 95% CI: 0.91–1.34. Similarly, non-signiﬁcant association was found
when dominant and recessive models were analyzed (CC + AC vs AA:
OR 1.15, 95% CI: 0.92–1.44 and CC vs AA + AC: OR 1.31, 95% CI: 0.83–
2.07, Table 3). Meta-analysis in subgroups according to race did not
yield any signiﬁcant association (data not shown). Similarly, when
meta-analysis was restricted to studies in Hardy–Weinberg Equilibrium
(HWE) no signiﬁcant associations were found (data not shown).
In all three meta-analyses heterogeneity was high since p-value
b0.05 and I2 N 50% (Table 3), while no publication bias was observed
(p-value N0.05 for all tests). Furthermore, Proteus phenomenon was
not detected in cumulative meta-analysis for the ΑΑ vs AC + CC
contrast, while for the A vs C and the CC vs AA + AC contrasts a time
trend was obvious (Table 4). Inﬂuential meta-analysis was also
performed and showed that no individual study inﬂuenced the effect
estimate (data not shown).
After that, a meta-analysis was carried out to test the association of
the same polymorphism (AGTR1 A1166C) with Chronic Kidney Disease
(CKD). From the 109 studies only eight were found eligible to provide
data for 812 patients and 4252 healthy subjects [36–38,40,42,44–46].
The characteristics of all studies are shown in Table 2B and numbers
of alleles and genotypes in Table S2.
Table 2A
Characteristics of studies included in the meta-analysis for the association of AGTR1 A1166C polymorphism with ESRD.
Study Year Country Race Cases Diagnostic criteria Controls Diagnostic criteria
Zsom M 2011 Hungary Caucasian 134 ESRD with primary glomerulonephritis interstitial
nephritis, hypertension related CKD
200 Healthy and age-matched controls
Elshamaa MF 2011 Egypt Other 44 Pediatric patients with ESRD based on e GFR on MHD 70 Healthy control subjects with no clinical signs of
vascular or renal disease and no family history
Huang HD 2010 China Asian 47 ESRD patients a) mainly on MHD, b)
transplant recipients c) IgA Nephropathy
120 Healthy subjects
Ayed Kh 2006 Tunisia African 131 Renal transplant recipients 50 Normotensive healthy subjects with clear yearly
examinations and negative hypertension history
Tabel Y 2005 Turkey Other 13 Children with end-stage renal insufﬁciency 287 Healthy adult subjects
Buraczynska M 2006 Poland Caucasians 745 Hemodialysis (n = 687) and peritoneal
dialysis (n = 58) patients
520 Healthy control subjects with no clinical signs of
vascular or renal disease and no family history of
renal disease
Lau YK 2004 Singapore Asian 32 Biopsy-proven primary IgAN-ESRD on MHD 94 Healthy subjects
Liu KP 2004 Taiwan Asian 16 Children with VUR progressing to ESRD 117 Unrelated healthy adults without renal disease
Lee KB 2003 Korea Asian 24 ADPKD-ESRD patients 105 Normotensive controls
Coll E 2003 Spain Caucasian 104 Dialysis patients 131 Healthy subjects with absence of nephropathy,
renal failure, diabetes mellitus, or cardiovascular
diseases
Papp F 2003 Hungary Caucasian 70 ESRD patients (20 pediatric, 50 adult) 150 Normotensive healthy subjects
(130 adults, 20 children)
Losito A 2002 Italy Caucasian 160 Hemodialysis patients 169 Healthy blood donors and hospital staff
Buraczynska M 2002 Poland Caucasian 430 Hemodialysis (n = 407) and peritoneal dialysis
(n = 23) patients
260 Healthy control subjects, with no clinical signs of
vascular or renal disease and no family history of
renal disease
Basset el-EA 2002 France Caucasian 294 Transplant recipients 181 Gender matched normal local subjects
Filler G 2001 Germany Caucasian 100 Pediatric transplant recipients 100 Healthy consecutive newborns
Frimat L 2000 France Caucasian 76 IgA-ESRD patients 960 Healthy Caucasian men in the Stanislas cohort
Gumprecht J 2000 Poland Caucasian 176 ESRD patients 352 Not reported
MHD: hemodialysis, ADPKD: Autosomal dominant polycystic kidney disease.
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not be found neither with per allele contrast nor with genotype con-
trasts. The ORs were 1.16 (95% CI: 0.83–1.64) for the per allele contrast
(C vs A), 1.06 (95% CI: 0.50–2.25) for the CC vs AA + AC contrast and
1.16 (95% CI: 0.82–1.63) for the CC + AC vs AA contrast. Excluding
one study of which the population was not in HWE did not grant signif-
icance to the association (data not shown). Heterogeneity was rather
low in all caseswith p-values N0.05 and I2 b 50% (Table 3), with no pub-
lication bias (p-value N0.05 for all tests, data not shown). No time trend
was observed in any of the contrasts (Table 4). No individual study was
found to inﬂuence the effect estimate of the remaining of the studies at
an inﬂuential meta-analysis (data not shown).
Afterwards, IgA Nephropathy was investigated for its association
with the A1166C polymorphism of the AGTR1. 36 studies were found
from the literature search, however, only ﬁve fulﬁlled all the appropriate
criteria and were used in the meta-analysis [31,37,38,47,48]. In total,
they contained 785 patients and 1373 controls (Tables 2C and S3) andTable 2B
Characteristics of studies included in the meta-analysis for the association of AGTR1 A1166C po
Study Year Country Race Cases Diagnostic criteria
Su SL 2012 Taiwan Asian 135 Patients with stages 3–5 CKD accord
Kidney Foundation [1], modiﬁed
ZsomM 2011 Hungary Caucasian 61 CKD patients with primary glomeru
nephritis, Hypertension related CKD
Elshamaa MF 2011 Egypt Egyptian 32 Pediatric patients with advanced CK
GFR under CT
Huang HD 2010 China Asian 83 IgAN non-ESRD patients
Hsu CC 2006 US African
Americans
307 CKD progression deﬁned as a) incre
b) hospitalization discharge, c) deat
renal disease [ICD-9] codes 581 to 5
Peruzzi L 2005 Italy Caucasian 50 Patients with renal hypodysplasia
Lau YK 2004 Singapore Asian 86 Biopsy-proven primary IgAN-non-E
Liu KP 2004 Taiwan Asian 58 VUR patients diagnosed by voiding
and graded as I–V
e GFR: estimated glomerular ﬁltration rate, CT: conservative treatment, ICD-9: international claall populations were in HWE. Meta-analysis for the allele contrast
(C vs A) produced an OR of 1.00 (95% CI: 0.84–1.17) indicating the
absence of any association of the A1166C polymorphism with IgA
Nephropathy. Likewise, no association was found in the other two
genotype contrasts (CC vs AA + AC and CC + AC vs AA) as shown in
Table 3. Heterogeneity was very low in all contrasts with p-values
N0.05 and I2 b 50% (Table 3) and no publication bias (p-value N0.05
for all tests, data not shown) was observed. Proteus phenomenon
was observed in the C vs A and the CC + AC vs AA contrast while in
the CC vs AA + AC contrast no time trend was observed (Table 4).
According to the inﬂuential meta-analysis performed, there was no
study to inﬂuence the ORs of the remaining studies (data not shown).
Subsequently, we wished to analyze the association of A1166C poly-
morphism of AGTR1 gene with Vesicoureteral Reﬂux (VUR). From the
literature search 14 studies were initially retrieved, but only three
could be used in themeta-analyses [40,49–51]. Altogether they included
174 patients and 216 healthy controls (Tables 2D and S4). However, thelymorphism with CKD.
Controls Diagnostic criteria
ing to US National 270 Healthy subjects age- and sex-matched
lonephritis, interstitial 200 Healthy and age-matched controls
D (stage 4) based on e 70 Healthy subjects with no clinical signs of vascular
or renal disease and no family history
120 Healthy subjects
ase in SCr ≥35 μmol,
h coded for chronic
83 or 585 to 588
3331 Not reported
50 Healthy subjects matched for sex, age and origin
SRD 94 Healthy subjects
cystourethroradiography 117 Unrelated healthy adult volunteers without renal
disease
ssiﬁcation of diseases, ninth revision, SCr: serum creatinine.
Table 2C
Characteristics of studies included in the meta-analysis for the association of AGTR1 A1166C polymorphism with IgA Nephropathy.
Study Year Country Race Cases Diagnostic criteria Controls Diagnostic criteria
Huang HD 2010 China Asian 130 IgAN by renal biopsy 120 Healthy subjects
Lau YK 2004 Singapore Asian 118 IgAN patients 94 Not reported
Maruyama K 2001 Japan Asian 95 IgAN patients 99 Healthy adult volunteers with no history of
renal disease or abnormal urinary ﬁndings
Frimat L 2000 France Caucasian 274 IgAN deﬁned as glomerulo-nephritis
with predominantly IgA deposits in the
mesangium of all glomeruli.
960 Healthy subjects in the Stanislas cohort
Pei Y 1997 Canada Caucasian 168 IgA by renal biopsy 100 Healthy subjects with no history of renal
disease or hypertension
4 G.G. Braliou et al. / Computational and Structural Biotechnology Journal 10 (2014) 1–7study of Liu and coworkers [40] could be used only for allele contrasts
since no genotype data was presented. As shown in Table 3, meta-
analysis under the C vs A allele contrast illustrated an OR 1.07 (95% CI:
0.68–1.67) suggesting no statistical signiﬁcant association. Likewise,
the genotype contrasts did not give any evidence for a signiﬁcant asso-
ciation of AGTR1 A1166C polymorphism with VUR (Table 3).
Between study heterogeneity was very low in all contrasts since
p-values N0.05 and I2 b 50% (Table 3). No publication bias was observed
with p-value N0.05 for all tests (data not shown). Time trend was
observed (Proteus phenomenon) for the C vs A contrast (Table 4),
while for the other two contrasts calculations could not be performed
since only two studies were included. In an inﬂuential meta-analysis
no individual study was found to inﬂuence the ORs of the rest (data
not shown).
3.2. A1332G polymorphism of AGTR2 gene
Finally, another polymorphism, A1332G of the AGTR2 gene was also
analyzed for its associationwith VUR. Initially 14 studieswere retrieved
from the literature search, yet, only three abided with the selection
criteria and were used in the meta-analysis [50,52,53]. Altogether,
they comprised 352 patients, 790 controls. All studies included
Caucasian populations (Tables 2E and S5). Because AGTR2 gene is on X
chromosome, one study [53] gave data formales and females separately,
and thus two cohorts were included in the initial meta-analysis. One
study [50] presented data only for males, and data from [52] was on
mixed population. Meta-analysis for the allele contrast on mixed popu-
lations revealed no association of AGTR2 A1332G polymorphism since
OR was 1.13 with 96% CI 0.66–1.92. No publication bias was observed
(p-value N0.05 for all tests, data not shown) and signiﬁcant heterogeneity
appeared (p-value 0.041 and I2 = 63.8%, Table 3). Time trend (Proteus
phenomenon) was also observed (Table 4). Meta-analysis for male pop-
ulations was additionally carried out, but did not present any signiﬁcant
association (Table 3). Thus, association of AGTR2 A1332G polymorphism
in males with VUR could not be proven (Table 3).
3.3. ΑGTR1 Α1166C and hypertension in ESRD patients
From the 17 studies we recruited in themeta-analysis for the associ-
ation of ΑGTR1 Α1166C with ESRD, three of themwere found to test the
inﬂuence of the variant on hypertension development in patients with
ESRD [28,39,42]. Data was given only for the ΑΑ vs CC + AC contrast
and thus we were able to perform a meta-analysis concerning thisTable 2D
Characteristics of studies included in the meta-analysis for the association of AGTR1 A1166C po
Study Year Country Race Cases Diagnostic criteria
Liu KP 2004 Taiwan Asian 74 VUR diagnosed by VCUG and graded
Haszon I 2002 Hungary Caucasian 77 VUR graded as I–V
Hohenfellner K 1999 Germany Caucasian 23 VUR diagnosed by radiological invest
VCUG and graded as I–V
VCUG: voiding cysto-urethrography.contrast. The OR was found equal to 0.98 with 95% CI: 0.68, 1.42 sug-
gesting no association of A1166C polymorphism with hypertension in
ESRD patients. According to Begg and Egger tests there was no publica-
tion bias and heterogeneity was very low (data not shown).
3.4. Multivariate meta-analyses for the association of AGTR1 A1166G
polymorphism with renal disease phenotypes
To validate the above results, multivariate meta-analyses were per-
formed. The analysis that was performed revealed no evidence for the
association of AGTR1 A1166C polymorphism with ESRD, since the ΑC
vs AA yields a p-value = 0.181 and OR: 1.14 (95% CI: 0.94, 1.37) and
the CC vs AA, an OR: 1.29 (95% CI: 0.78, 2.15) and p-value = 0.319
(Table 5). Likewise,multivariatemeta-analysis did not detect any signif-
icance for the association of this polymorphism with CKD. No associa-
tion of AGTR1 A1166C polymorphism with IgA Nephropathy could be
proven since the ORs were 1.01 (95% CI: 0.81, 1.25) and 0.95 (95% CI:
0.61, 1.47) for theACvs AAandCC vs AA contrasts respectively. Similarly,
multivariate meta-analysis suggested no signiﬁcant association with
VUR for either dominant ΑC vs AA [OR: 1.29 (95% CI: 0.73, 2.29)] or
the recessive contrast [CC vs AA [OR: 0.16 (95% CI: 0.02, 1.39)]]
(Table 5). Nevertheless, these ﬁndingswere expected since themajority
of the univariate tests were unable to show an association. Multivariate
meta-analysis could help in avoiding an inﬂation of the Type I error rate
(i.e. reduce false positive ﬁndings), but it does not offer greater statisti-
cal power.
4. Discussion
The Renin–Angiotensin System plays a pivotal role in the physiology
of the kidneys. In non-dialyzed CKD patients, ACE inhibitors and AGTR
blockers are used as the treatment of choice since they grant greater
survival [10,54]. It has been recently shown [55] that AGTM235T gene
polymorphism is associated with ESRD susceptibility in Caucasians. In
addition, a meta-analysis [56] demonstrated genetic association of ACE
I/D polymorphism with ESRD risk which actually correlates well with
ﬁndings that increased circulating ACE levels in plasma are related
with ACE I/D polymorphism [57].
Both A1166C of AGTR1 and A1332G of AGTR2 are within the 3′
untranslated regions of the genes. Though these polymorphisms do
not lead to amino acid substitutions, these 3′ untranslated regions
may play a pivotal role in the genomic context of the genes and may
inﬂuence their expression levels, since they could result in defects inlymorphism with VUR.
Controls Diagnostic criteria
as I–V 117 Unrelated healthy adult volunteers without renal disease
80 Healthy blood donors
igations including 19 boys with absence of any disorder of the urinary tract
Table 2E
Characteristics of studies included in the meta-analysis for the association of AGTR2 A1332G polymorphism with VUR.
Study Year Country Race Cases Diagnostic criteria Controls Diagnostic criteria
Rigoli L 2004 Italy Caucasian 27 Primary VUR according to the International Reﬂux
Classiﬁcation [43]
92 Children with no renal disease
Yoneda A 2002 Ireland Caucasian 302 Male and female VUR patients from 88 families 679 Healthy controls, and non-affected family members
Hohenfellner K 1999 Germany Caucasian 23 Male VUR patients (grades I–V, according to the
International Reﬂux Classiﬁcation)
19 Healthy boys with absence of any disorder of the
urinary tract
Table 3
Univariate meta-analysis for all contrasts performed for both AGTR1 (A1166C) and AGTR2 (A1332G) polymorphisms for its association with diseases as indicated.




95% conﬁdence interval Cochran's Q p-value for
heterogeneity
I2 (%) Between studies
variance (τ2)
A1166C/AGTR1 A vs C ESRD 16 1.10 0.91 1.34 53.06 0.000 71.7% 0.097
CKD 7 1.16 0.83 1.64 10.41 0.109 42.3% 0.087
IgAN 5 0.99 0.84 1.17 2.31 0.678 0.0% 0.000
VUR 3 1.07 0.68 1.67 2.29 0.318 12.8% 0.022
CC vs AA + AC ESRD 14 1.31 0.83 2.07 30.80 0.004 57.8% 0.370
CKD 6 1.06 0.50 2.25 3.16 0.675 0.0% 0.000
IgAN 5 0.94 0.62 1.45 0.51 0.973 0.0% 0.000
VUR 2 0.14 0.02 1.22 0.10 0.749 0.0% 0.000
CC + AC vs AA ESRD 15 1.15 0.92 1.44 38.42 0.000 63.6% 0.108
CKD 7 1.16 0.82 1.63 11.03 0.087 45.6% 0.091
IgAN 5 1.00 0.81 1.23 3.05 0.550 0.0% 0.000
VUR 2 1.15 0.66 2.01 0.36 0.551 0.0% 0.000
A1332G/AGTR2 A vs C VUR 4 (mixed) 1.13 0.66 1.92 8.28 0.041 63.8% 0.649
2 (males) 0.67 0.41 1.10 0.61 0.433 0.0% 0.000
Table 4





A1166C/AGTR1 CKD C vs A 0.789 NO
CC vs AA + AC 0.501 NO
AA vs CC + AC 0.432 NO
ESRD C vs A 0.017 YES
CC vs AA + AC 0.000 YES
AA vs CC + AC 0.783 NO
IgA Nephropathy C vs A 0.008 YES
CC vs AA + AC 0.488 NO
AA vs CC + AC 0.000 YES
VUR C vs A 0.000 YES
A1332G/AGTR2 VUR G vs A 0.000 YES
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tion of regulatory elements such enhancers and insulators [2,58]. The
deletion/insertion polymorphism in intron 16 of the ACE gene is an
example of such non-coding sequence polymorphisms that inﬂuence
gene function. Moreover, Sethupathy et al. [59] have shown that there
is a miRNA from chromosome 21, namely miR155, that downregulates
the expression of the 1166A allele but not of the 1166C. They hypothe-
size that the 1166C allele is associated with hypertension just because
miR155 cannot negatively control the expression levels of AGTR1.
In view of the above data, considering the fact that AGT, ACE and
AGTRs perform in the same biochemical pathways, and taken the num-
ber of case–control studies investigating relationship of AGT receptors
gene variants with kidney diseases, in the present meta-analysis we
set out to explore putative genetic associations of AGTR1 and AGTR2
gene polymorphismswith renal diseases. We investigated these associ-
ations for sub-group renal diseases such as ESRD, CKD, IgANephropathy
and VUR.
Though very promising, and despite the inclusion of 2596 patients
and 3866 healthy controls from 17 studies, no statistical signiﬁcant
association of AGTR1 A1166C polymorphism with ESRD was found
either in the allele contrasts or in the dominant and recessive models.
Subgroup analysis by ethnicity or by studies in HWE did not change
this pattern of results. The main analysis revealed signiﬁcant heteroge-
neity under the allele contrast, the recessive and dominant models, im-
plying that these results may not change even in a future meta-analysis
thatwould contain additional studies. This is further corroborated by our
ﬁndings showing that contrasts for the allele, recessive and dominant
models needed two to three times more subjects to obtain signiﬁcant
results (data not shown) according to calculations based on the
Barrowman et al. method [60]. Multivariate meta-analysis did not
change the signiﬁcance of the results. Thus no signiﬁcant association
of AGTR1 A1166C polymorphism with ESRD was proven.
Similarly, meta-analyses revealed lack of association of AGTR1
A1166C polymorphism with CKD and non-signiﬁcant heterogeneity
under the allele contrast, the recessive and dominant models. This
pattern did not change under subgroup analysis by race and by HWE,
neither did it change when multivariate meta-analysis was performed.
Time–trend related bias (Proteus phenomenon) was not detectedreinforcing the absence of association of AGTR1 A1166C with CKD. Be-
sides, due to low heterogeneity and according to our calculation (need-
ing four to 1500 timesmore subjects to reach signiﬁcance) based on the
Barrowman et al. method [60], we believe that the absence of associa-
tion of AGTR1 A1166C polymorphism with CKD is rather factual.
Similarly, no association was found between AGTR1 A1166C poly-
morphism and IgA Nephropathy and VUR, under all contrasts (allele
and genotypes) tested. While for the association with IgAN the absence
of association was pretty clear, the ORs for the association with VUR
were ﬂuctuating between various contrasts, due to the very small
number of studies (three for allele contrast and two for the genotypes
contrasts). Further evaluations suggested very low heterogeneity of
the studies and no publication bias. Time–trend related bias (Proteus
phenomenon) detected in thesemeta-analyses denote that more studies
will improve the signiﬁcance of our results. Additionalmultivariatemeta-
analyses that we performed conﬁrmed the lack of association of AGTR1
A1166C polymorphism with IgAN and VUR.
Furthermore, we attempted to investigate the involvement of the
A1332G polymorphism of the AGTR2 gene, located in the X chromo-
some, in the pathogenesis of VUR. Meta-analysis of the available data
Table 5




Contrast OR 95% conﬁdence
interval
ESRD 14 AC vs AA 1.14 0.94 1.37
CC vs AA 1.29 0.78 2.15
CKD 6 AC vs AA 1.17 0.73 1.88
CC vs AA 1.08 0.46 2.52
IgA Nephropathy 5 AC vs AA 1.01 0.81 1.25
CC vs AA 0.95 0.61 1.47
VUR 2 AC vs AA 1.29 0.73 2.29
CC vs AA 0.16 0.02 1.39
6 G.G. Braliou et al. / Computational and Structural Biotechnology Journal 10 (2014) 1–7from three studies including bothmale and female populations showed
no association under the allele contrast.
It should be mentioned that the absence of any association of the
two aforementioned polymorphisms was relatively unexpected, con-
sidering the fact that polymorphisms of the other two RAS proteins
genes (AGT and ACE) do associate with renal diseases. Nevertheless,
no Genome Wide Association Study (GWAS) revealed AGTRs polymor-
phisms as putative markers for renal disease progression. However,
these ﬁndings did not discourage our study because GWASs do have
some limitations since they often explain only a few percent of the
variance of the phenotype, and it is difﬁcult to assign mechanistically
the loss of function of a speciﬁc gene to one polymorphism [5,61]. In
support of our ﬁrst idea of AGTR association with renal diseases is the
fact that the AGT M235T and AGTR1 A1166C polymorphisms have
been associated with diabetic nephropathy in a meta-analysis [62],
but not with diabetes (to the best of our knowledge). On the other
hand, and in support of our results, a publication came during the prep-
aration of the present manuscript showing lack of association of AGTR1
A1166C polymorphism with the risk for ESRD [63], though including
only eight studies as compared to 17 that we included in the present
study. Taken together our data suggest that neither AGTR1 A1166C nor
AGTR2 A1332G polymorphisms can be used as reliable markers to
predict the risk for CKD, ESRD, IgAN or VUR.
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